Kelley Jones Named to 2026 Lott IMPACT Trophy Watchlist
STARKVILLE, Miss. — Mississippi State cornerback Kelley Jones has been named to the watchlist for the 2026 Lott IMPACT Trophy, recognizing top defensive players who demonstrate integrity, maturity, performance, academics, community involvement and tenacity. The award, named after NFL Hall of Famer Ronnie Lott, honors defensive athletes who excel both on and off the field.
Jones’ Standout 2025 Season
Jones, a Clarksdale, Mississippi native, enters his redshirt junior season after a standout 2025 campaign. He started all 13 games last season, recording 34 tackles, 11 pass breakups, and two interceptions. Pro Football Focus highlighted his exceptional performance, noting he allowed only 11 receptions on 38 targets, a 28.9% completion rate—the best among all cornerbacks who played at least half of their team’s snaps. His 11 receptions allowed also led SEC cornerbacks.
Jones earned third-team All-SEC honors from the league’s coaches and was ranked No. 147 on CBS’s Top 150 players for 2025. His preseason recognition continues as he was recently ranked No. 25 on On3’s Top 100 Players of 2026.
About the Lott IMPACT Trophy
The Lott IMPACT Trophy is presented by the Lott IMPACT Foundation, a nonprofit organization founded by Ronnie Lott. The winner is selected by a national panel, including former winners, media members, coaches, and IMPACT Foundation board members. The award will be presented at a black-tie gala at The Pacific Club on December 9, 2026.
“This recognition underscores Kelley’s dedication to excellence and his role as a leader on and off the field,” said Mississippi State football officials. “His performance and character align perfectly with the values the Lott IMPACT Trophy represents.”
Looking Ahead
As the 2026 season approaches, Jones’ inclusion on the watchlist signals his potential to become one of the nation’s top defensive players. Fans can follow Mississippi State football on X, Facebook, and Instagram for updates by searching for “HailStateFB.”
Source: Sports Mississippi
Worth a look
- Florida Removes Climate Change References From Science Textbooks
- A Day in the Life of ND Game Warden Josh Hedstrom
- Oregon State Capitol in Salem (news-usa.today)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)